期刊
CURRENT OPINION IN UROLOGY
卷 19, 期 5, 页码 488-493出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOU.0b013e32832eb3a0
关键词
bladder cancer; molecular diagnostics; tumor markers
资金
- NCI/NIH [R01 CA-72821-06A2]
- NATIONAL CANCER INSTITUTE [R01CA072821] Funding Source: NIH RePORTER
Purpose of review Bladder cancer remains a highly prevalent and lethal malignancy. Early diagnosis and prompt treatment have been shown to improve survival at both initial diagnosis and recurrence. A vast number of tumor markers have been identified and rigorously evaluated in attempts to improve noninvasive diagnostic accuracy of bladder cancer. Hematuria was the first tumor marker in a field that has grown to include soluble markers, cell-surface antigens, cell-cycle-related proteins, and genetic alterations. We aim to provide a critical appraisal of newer markers and the current state of research. Recent findings The number of tumor markers identified has been exponentially increasing. For a variety of reasons, many are unsuitable for clinical practice. More promising recent markers include those discovered in the fields of genomics, proteomics, and epigenetics. Much of the recent work is focused on molecular genetic pathways in bladder cancer. Summary The field of bladder cancer tumor markers remains a rapidly evolving area in which newer markers are constantly identified, evaluated, and often discarded if they do not add significantly to the urologists' armamentarium. Newer markers rely on genetic rearrangements, molecular changes, and cell-cycle-related proteins. Work is currently being done to identify the most promising markers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据